June 7, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Chimerix receives U.S. Food and Drug Administration approval forbrincidofovir for the treatment of smallpox
TOKYO, Japan, June 7, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio")
today announced that Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") announced on June 4,2021 (US EST) that the U.S. Food and Drug Administration (FDA) has granted brincidofovir (BCV)
tablets and oral suspension approval for the treatment of smallpox. It is approved for adult andpediatric patients, including neonates.
Chimerix developed the BCV oral formulations as a medical countermeasure for smallpox under an
ongoing collaboration with the Biomedical Advanced Research and Development Authority (BARDA),
part of the office of the Assistant Secretary for Preparedness and Response within the U.S.
Department of Health and Human Services. Chimerix looks forward to advancing its discussions
with BARDA toward a procurement contract to support national preparedness. For furtherinformation, please see Chimerix’s website: https://ir.chimerix.com/press-releases
SymBio, pursuant to a license agreement with Chimerix entered into on September 30, 2019,obtained the exclusive worldwide rights to develop, manufacture, and commercialize BCV in all
human indications, excluding the prevention and treatment of orthopox infections (which includes
smallpox and monkeypox). SymBio is preparing to initiate a global study of BCV targeting adenovirus(AdV) infections occurring after hematopoietic stem cell transplantation.
The Company does not expect the information presented to have a material impact on its financialoutlook for the fiscal year ending December 31, 2021.

1

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About Smallpox
Smallpox is a highly contagious disease caused by the variola virus. Historically, smallpox was one ofthe deadliest diseases in history with a case fatality rate of approximately 30%. Despite successful
eradication of smallpox in the 1970s, there is considerable concern that variola virus could reappear,
either through accidental release or as a weapon of bioterrorism. According to the U.S. Centers for
Disease Control and Prevention (CDC), variola virus is ranked in the highest risk category forbioterrorism agents (Category A) due to its ease of transmission, high mortality rate, and potential tocause public panic and social disruption.
About Anti-viral Drug Brincidofovir
Brincidofovir (BCV) is a lipid-conjugate of cidofovir (an antiviral drug already approved and marketedin the U.S. and Europe, but unapproved in Japan; “CDV”). In addition to its antiviral effect, BCV wasintended to be designed to have improved safety profile as compared to CDV. Therefore, BCV isexpected to be an effective treatment for a wide range of DNA viruses (e.g., herpesviruses such as
cytomegalovirus (CMV), adenovirus (AdV), BK virus, papillomavirus, etc.).
Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent that can reduce the riskof nephrotoxicity, which is a serious side effect of CDV.
SymBio entered into an exclusive global license agreement with Chimerix for brincidofovir (BCV) on
September 30, 2019. Under the terms of the agreement, Chimerix grants SymBio exclusive worldwide
rights to develop, manufacture, and commercialize BCV in all human indications, excluding theprevention and treatment of orthopox infections (which includes smallpox and monkeypox).
SymBio aims to further globalize business, establish an integrated system for the supply of highquality pharmaceutical products, and grow as a specialty pharmaceutical company through theexclusive global license for BCV. To develop global operations, the Company is considering
partnerships that will utilize regional characteristics of the target diseases and striving to maximize
the business value of the products and to deliver to patients who need our products as soon aspossible. The Company aims to serve the patients not only in Japan but also in Europe and the U.S.
market where the market size for organ transplantation is large, and Asia, including the Chinese
market.
For further information, please see the SymBio’s press release dated October 1, 2019,https://www.symbiopharma.com/news/20191001.pdf

2About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating theadvancement of innovative medicines that make a meaningful impact in the lives of patients livingwith cancer and other serious diseases. Its three most advanced clinical-stage development programs
are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical
countermeasure for smallpox and is currently under review for regulatory approval in the UnitedStates. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant
glioma and a confirmatory response rate assessment is expected later this year. DSTAT is indevelopment as a potential first-line therapy in acute myeloid leukemia. For further information,please visit the Chimerix website, www.chimerix.com.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called
SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.

3